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SUMMARY
Protein ubiquitination is a dynamic and reversible process of adding single ubiquitin molecules or 
various ubiquitin chains to target proteins. Here, using multidimensional omic data of 9,125 tumor 
samples across 33 cancer types from The Cancer Genome Atlas, we perform comprehensive 
molecular characterization of 929 ubiquitin-related genes and 95 deubiquitinase genes. Among 
them, we systematically identify top somatic driver candidates, including mutated FBXW7 with 
cancer-type-specific patterns and amplified MDM2 showing a mutually exclusive pattern with 
BRAF mutations. Ubiquitin pathway genes tend to be upregulated in cancer mediated by diverse 
mechanisms. By integrating pan-cancer multiomic data, we identify a group of tumor samples that 
exhibit worse prognosis. These samples are consistently associated with the upregulation of cell-
cycle and DNA repair pathways, characterized by mutated TP53, MYC/TERT amplification, and 
APC/PTEN deletion. Our analysis highlights the importance of the ubiquitin pathway in cancer 
development and lays a foundation for developing relevant therapeutic strategies.
In Brief
Ge et al. analyze a cohort of 9,125 TCGA samples across 33 cancer types to provide a 
comprehensive characterization of the ubiquitin pathway. They detect somatic driver candidates in 
the ubiquitin pathway and identify a cluster of patients with poor survival, highlighting the 
importance of this pathway in cancer development.
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INTRODUCTION
The highly conserved ubiquitin pathway serves as a crucial regulator, mediating a myriad of 
cellular events that underlie the development of an assortment of cancer types (Di Fiore et 
al., 2003; Hoeller and Dikic, 2009; Nakayama and Nakayama, 2006). The ubiquitin 
molecule is an 8.5-kDa, 76-amino-acid globular protein with a complex 3-dimensional 
surface topology that is able to form various types of ubiquitin chains, thereby acting as a 
robust, post-translational protein modifier (Weissman, 2001). The canonical addition of 
ubiquitin to a protein substrate involves the consecutive actions of three main families of 
ubiquitination (UBQ) enzymes through a coordinated enzymatic cascade (Fuchs, 2002; Gao 
et al., 2013). In the first step, a thiol-ester bond is formed between a ubiquitin-activating 
enzyme (E1) and the carboxy-terminal glycine of ubiquitin. The next step involves the 
transfer of the activated ubiquitin from the E1 enzyme to a ubiquitin-conjugating enzyme 
(E2) via a trans-thiolation reaction. Finally, a ubiquitin ligase (E3), which functions as a 
scaffold protein binding both the E2 enzyme and the target protein, mediates the transfer of 
ubiquitin from the E2-ubiquitin conjugate, most commonly onto the ε-amino group of a 
lysine residue on the protein substrate, thus forming an isopeptide bond (Hoeller and Dikic, 
2009; Weissman, 2001). Because UBQ is a dynamic and reversible process, deubiquitinating 
enzymes (DUBs) fulfill a converse role in the pathway by deconjugating ubiquitin from 
proteins entirely or trimming poly-ubiquitin chains, thereby enhancing regulation in the 
ability to abrogate or modify ubiquitin protein modifications (Komander et al., 2009; 
Weissman, 2001). Recognition of distinct UBQ patterns by downstream effectors elicits 
various cellular functions: it can mark proteins for degradation via the proteasome, alter their 
subcellular localization, affect their activity, and promote or prevent protein interactions.
In recent years, the role of the ubiquitin pathway in cancer has gained attention for two main 
reasons. First, both basic and translational studies have shown extensive evidence connecting 
the malfunction of the ubiquitin pathway with tumor initiation and progression. For 
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example, UBQs have been found to be tightly associated with many cancer-related 
pathways, including cell-cycle progress, p53 activation, DNA damage repair, apoptosis, 
nuclear factor κB (NF-κB), and receptor tyrosine kinase pathways (Hoeller and Dikic, 2009; 
Li et al., 2003; Lind et al., 2006; Massoumi et al., 2006; Meetei et al., 2003; Weissman, 
2001); DUBs are implicated in many of the same cancer pathways as UBQs; in addition, 
they are associated with chromatin remodeling, WNT signaling, and transforming growth 
factor β (TGF-β) signaling (Dey et al., 2012; Dupont et al., 2009; Luise et al., 2011; 
Tauriello et al., 2010; Wicks et al., 2005; Zhao et al., 2009). Second, targeting the ubiquitin 
pathway for regulating target protein levels, rather than for its biological activity, has 
emerged as a promising therapeutic strategy for cancer patients. Because many oncoproteins 
are subject to UBQ-dependent degradation, enhancing UBQ or targeting certain DUBs may 
lead to destabilization or functional inactivation of key oncoproteins, including some 
undruggable targets such as MYC and β-catenin (Salami and Crews, 2017; Xiao et al., 
2016). A few drugs targeting the ubiquitin pathway have been approved by the U.S. Food 
and Drug Administration (FDA) (Huang and Dixit, 2016; Swisher et al., 2017).
Given the pervasive impact and clinical utility of the ubiquitin pathway across many cancer 
types, it is important to curate genomic insights into the role of this pathway in cancer 
development and treatment through a systematic, pan-cancer analysis. The Cancer Genome 
Atlas (TCGA) has generated genomic, transcriptomic, proteomic, epigenomic, and clinical 
data over large patient cohorts, providing an unprecedented opportunity for such an analysis 
(Cancer Genome Atlas Research Network et al., 2013). We performed a molecular 
characterization of UBQ and DUB genes across 9,125 patients from 33 cancer types (Table 
S1). To maximize the chance of making scientific and clinical findings, we compiled a 
comprehensive list of 929 UBQ-related genes (including both validated and computationally 
predicted E1 and E2 enzymes, as well as E3 ligases and their associated adaptor genes, 
termed UBQ genes hereafter for simplicity) and 95 DUB genes (see curation details in 
STAR Methods, Figure S1, and Table S2). Our analysis will not only further elucidate the 
role of the ubiquitin pathway in cancer development but also directly inform researchers and 
clinicians as to possible driver genes and eminently druggable targets for future clinical trials 
and therapeutics.
RESULTS
Mutation Driver Candidates of UBQ and DUB Genes
Based on TCGA mutation data of whole-exome sequencing, we examined the somatic 
mutation profiles of UBQ and DUB genes in 33 cancer types. Overall, across 8,811 non-
hypermutated cancer samples, the mutation frequency was low for both UBQ and DUB 
genes, with an average mutation number per patient of 4.5 and 0.5, respectively. To identify 
potential cancer drivers, we employed two complementary computational approaches. First, 
we used a ratiometric method for nominating cancer driver genes based on the enrichment of 
hotspot or loss-of-function (LoF) mutations among all mutations observed in a gene (Figure 
1A) (Vogelstein et al., 2013). In this pan-cancer analysis, we identified 19 UBQ/DUB genes 
with >30% hotspot mutations and 29 genes with >30% LoF mutations (FBXW7 was 
identified by both criteria). Second, we used MutSigCV (Lawrence et al., 2013) to pinpoint 
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UBQ/DUB gene drivers whose mutation rates were significantly higher than the background 
expectation within each cancer type. Using a q value cutoff of 0.1, we identified 23 such 
genes in 23 cancer types (Figure 1B). In total, these two methods identified 55 driver 
candidates, and their overall mutation frequency ranged from 0.2% to 7.2% (Figure S2). We 
then mapped these 55 putative cancer drivers to different gene categories in the ubiquitin 
pathway and found no specific enrichment patterns (Figure 1C): there were no E1 enzyme 
driver genes of the driver genes detected, two were E2 enzyme drivers, four were DUB 
drivers, and the rest (49) were E3 ligases and associated adaptors. Among 15 driver genes 
identified by both methods, SPOP, KEAP1, and CHD4 were enriched with hotspot 
mutations, while BAP1, CDH1, CUL3, EP300, KDM5C, MAP3K1, NSD1, RNF43, TLE1, 
VHL, and LZTR1 contained excessive LoF mutations. This analysis provides a systematic 
view of potential mutation drivers among UBQ and DUB genes.
Of particular interest, FBXW7 showed enrichment of both hotspot and LoF mutations 
(Figure 1A). The FBXW7 protein functions as the substrate recognition component of the 
SKP1-CUL1-F-box protein (SCF) ubiquitin ligase complex. As an established tumor 
suppressor gene, it mediates the degradation of cell-cycle promoters or oncoproteins, 
including cyclin E (Koepp et al., 2001; Siu et al., 2012), c-Myc (Yada et al., 2004), c-Jun 
(Wei et al., 2005), Notch (Gupta-Rossi et al., 2001), Mcl1 (Ren et al., 2013), and mTOR 
(Mao et al., 2008). To gain more insight into its mutational profile, we examined the 
mutation distributions of FBXW7 in different cancer types and found three distinct patterns 
(Figure 2A): (1) hotspot mutations were enriched in two uterine cancer types, uterine corpus 
endometrial carcinoma (UCEC), and uterine carcinosarcoma (UCS); (2) LoF mutations were 
enriched in skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), lung 
squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD), rectum adenocarcinoma 
(READ), and esophageal carcinoma (ESCA); and (3) the proportions of both hotspot and 
LoF mutations were high in head and neck squamous cell carcinoma (HNSC), cervical 
squamous cell carcinoma and endocervical adenocarcinoma (CESC), bladder urothelial 
carcinoma (BLCA), and colon adenocarcinoma (COAD). Consistent with previous studies, 
FBXW7 contains three notable missense mutation hotspots (R465, R479, and R505) in the 
second, third, and fourth WD40 domains that recognize the consensus phospho-motif 
located in its substrate (Figure 2B) (Hao et al., 2007). Figure 2C shows the FBXW7 
mutation distributions for the hotspot mutation-enriched cancer types and the LoF mutation-
enriched cancer types. The three missense hotspots accounted for 49% (38 of 77) of the 
FBXW7 mutations observed in UCEC and UCS. The contrasting mutation patterns of 
FBXW7 mutations may reflect tissue-specific roles of FBXW7 substrates or different 
FBXW7-mediated oncogenic mechanisms in different tumor contexts. We further assessed 
the occurrence of FBXW7 mutations with those in clinically actionable cancer genes and 
revealed that mutations in FBXW7 and PIK3CA showed mutual exclusivity in three cancer 
types: CESC, BLCA, and LUSC (Figure 2D), suggesting that mutations in these two genes 
confer similar functional consequences. Patients with FBXW7 or phosphatidylinositol 3-
kinase (PI3K) pathway mutations (mutations found in PIK3CA, PTEN, and STK11) had 
higher PI3K pathway expression activity than patients without such mutations (Figure 2E).
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Somatic Copy-Number Alteration Patterns of UBQ and DUB Genes
To infer somatic copy-number alteration (SCNA) drivers, we used GISTIC2 (Mermel et al., 
2011) to identify significant focal deletion and amplification peaks in each of 33 cancer 
types. UBQ and DUB genes showed similar overall SCNA profiles in terms of the 
amplification and deletion gene fractions across cancer types (Figures S3A and S3B). To 
more rigorously assess the SCNA significance of UBQ and DUB genes against the cancer-
type-specific background rate, we calculated the enrichment of UBQ and DUB genes that 
reside in the amplification or deletion peaks identified by GISTIC2 (q < 0.25) using Fisher’s 
exact test (Figures 3A, S3C, and S3D). Four cancer types (kidney renal clear cell carcinoma 
[KIRC], SKCM, cholangiocarcinoma [CHOL], and pancreatic adenocarcinoma [PAAD]) 
showed significant deletion peak enrichments, while no cancer types showed significant 
amplification peak enrichment (p < 0.01) (Figure 3A). Figure 3B shows the top 30 
frequently detected UBQ and DUB genes across different cancer types, including ARNT, 
MDM2, and FAM63A (amplification) and PARK2, ING5, and ING2 (deletion).
Among the top UBQ/DUB genes with frequent SCNAs, MDM2 was significantly amplified 
in 11 cancer types. The protein product of this gene is a negative regulator of TP53 and a 
therapeutic target under intensive clinical investigation. We therefore focused on MDM2 to 
examine its mutually exclusive pattern with (1) amplification of other UBQ/DUB genes and 
(2) somatic mutations of clinically actionable genes. Among UBQ and DUB genes, we 
found a mutually exclusive pattern of MDM2 and SKP2 amplifications in LUAD (Figure 
S3E), suggesting convergence of their functions on the same downstream effectors. In 
agreement with this notion, previous studies have shown that MDM2 prevents the binding of 
the E2F1 protein to its E3 ligase SCFskp2, thus inhibiting E2F1 degradation (Zhang et al., 
2005). For clinically actionable genes, we found that MDM2 amplifications were mutually 
exclusive to BRAF and ATM mutations in SKCM and BLCA, respectively (Figures 3C and 
S3F). BRAF kinase domain mutations, such as V600E, result in a constitutively activated 
form of the protein in around 50% of SKCM patients (45.1% in this study), which then leads 
to stimulated mitogen-activated protein kinase (MAPK) signaling and induces tumor cell 
proliferation. The mechanism through which MDM2 antagonizes p53 functions is acting as 
the p53-specific E3 ligase and promoting p53 degradation, which then leads to reduced cell 
apoptosis. We observed MDM2 amplification in 4.1% of the SKCM samples in this study, in 
which p53 protein levels were significantly lower than in samples with BRAF mutations 
alone or with neither BRAF mutations nor MDM2 amplifications. This pattern was not 
observed at the mRNA expression level (Figure 3D). These results confirmed the function of 
MDM2 acting as an E3 ligase targeting the p53 protein for degradation. Furthermore, the 
mutually exclusive pattern of MDM2 amplification and BRAF mutation suggests that a 
reduced p53 pathway or induced MAPK signaling can serve as an impetus for aberrant 
tumor cell proliferation (Figure 3E). This intriguing pattern implies that restoring p53 
function and blocking the MAPK pathway at the same time could be more beneficial to 
SKCM patients than interfering with either pathway alone. Studies have shown increased 
apoptosis and inhibition of melanoma growth by combining a BRAF inhibitor and p53 
reactivation (Lu et al., 2013; Saiki et al., 2014).
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Upregulated mRNA Expression of UBQ/DUB Genes in Cancer
To investigate the patterns of dysregulation of UBQ and DUB genes in cancer, we examined 
their gene expression using mRNA expression data of paired tumor and normal samples 
from 16 cancer types, because such paired-sample comparisons help reduce the effects of 
potential confounding factors. We identified differentially expressed genes (Wilcoxon signed 
rank test) between tumors and their matched normal samples and performed gene 
enrichment using gene set enrichment analysis (GSEA) (Subramanian et al., 2005). The 
combined set of UBQ and DUB genes showed significant enrichment in genes that were 
upregulated in tumor tissues in 7 of the 16 cancer types examined (CHOL, COAD, liver 
hepatocellular carcinoma [LIHC], LUAD, LUSC, PRAD, and BLCA), and more genes were 
upregulated than downregulated in these diseases (q < 0.1) (Figures 4A, 4B, and S4A). In 
contrast, only thyroid cancer (thyroid carcinoma [THCA]) showed a significant opposite 
pattern (q < 0.1) (Figures 4A and 4B). We obtained similar results for UBQ and DUB genes 
separately (Figure 4A).
To examine the molecular mechanisms underlying the UBQ/DUB mRNA upregulation in 
the seven cancer types, we further integrated SCNA, DNA methylation, and microRNA 
(miRNA) expression data and compared the patterns of upregulated UBQ/DUB genes to 
those of neutral ones (i.e., genes showing no significant differential mRNA expression). 
First, in 6 of the 7 cancer types, upregulated genes showed a significantly higher proportion 
of copy-number amplifications than did neutral genes (chi-square test, q < 0.01) (Figure 4C, 
top), highlighting the significant role of somatic copy-number gain in increasing UBQ/DUB 
gene expression in tumor samples. Second, for four cancer types with miRNA expression 
data and sufficient matched tumor and normal pairs (n > 20), compared to neutral genes, 
upregulated genes showed a significantly higher proportion of their reduced miRNA 
regulators in tumor samples of LIHC and LUAD (chi-square test, q < 0.1) (Figure 4C, 
middle), suggesting that miRNA-mediated gene repression contributes to the increased 
UBQ/DUB mRNA expression. Third, for six cancer types with DNA methylation data and 
sufficient matched tumor and normal pairs (n > 20), compared to neutral genes, upregulated 
genes showed a significantly higher proportion of reduced methylation levels in tumor 
samples of COAD and LUAD (chi-square test, q < 0.01) (Figure 4C, bottom), suggesting 
notable contributions of methylation-mediated gene silencing in these two cancer types. 
Finally, across cancer types, ~71% of upregulated UBQ/DUB genes were affected by these 
mechanisms and ~10% of them were mediated by more than one mechanism (Figures 4C, 
right, and S4B). These results provide a quantitative view of how different mechanisms 
contribute to the dysregulation of UBQ and DUB genes in tumor samples.
In addition, we performed an analysis to identify key miRNA regulators of UBQ and DUB 
genes. We inferred coding gene targets of 1,855 miRNAs by integrating both sequence 
information of target genes and the co-expression of the corresponding mRNA-miRNA pairs 
(STAR Methods). Several master miRNA regulators for UBQ and DUB genes emerged from 
this analysis (Figure S5), including the mir-200 family (mir-200a, mir-200b, mir-200c, 
mir-141, and mir-429), the mir-17/92 cluster (mir-17, mir-18a, mir-19a, mir-20a, and 
mir-19b-1), and mir-7-1.
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Integrated Genomic Analysis of UBQ and DUB Genes
In addition to the preceding single-platform-oriented analysis, we integrated the data from 
mRNA expression, SCNA profiles, and DNA methylation to gain a more comprehensive 
picture of UBQ/DUB molecular patterns. We first normalized mRNA expression and DNA 
methylation data by Z scores within each cancer type to minimize tissue effects and then 
clustered the samples based on three data types separately. For each data type, all samples 
were appropriately clustered into four groups (Figure 5A–5C). Using the cluster-of-cluster 
assignment (COCA) strategy (Hoadley et al., 2014), we then represented each platform-
specific cluster as binary vectors and re-clustered all samples across the three data types, 
which revealed three robust clusters (COCA1, COCA2, and COCA3) (Figures 5D and S6A). 
The samples were relatively evenly distributed among different cancers, and overall, 55%, 
25%, and 20% of the samples belonged to COCA1, COCA2, and COCA3, respectively.
We next assessed the clinical relevance of these three clusters. Because patient survival time 
generally reflects the progression of the disease and represents a key clinical variable, we 
performed survival analysis within each cancer type (log-rank test). The COCA clusters 
showed significant association with overall survival for 10 of 30 cancer types with a 
sufficient sample size and follow-up time (Figure 5E). In addition, the COCA clusters 
showed similar significant associations with the disease-specific survival times for nine 
cancer types (Figure 5E). Strikingly, in all these cancer types, COCA2 was always 
associated with worse prognosis (Figures 5F, S6B, and S6C). In addition, we examined the 
correlations of COCA clusters with established tumor subtypes and found significant 
correlations in multiple cancer types (Figure S6D). Altogether, these results highlight the 
potential clinical utility of this UBQ/DUB-driven subtyping.
Biological Pathways and Molecular Drivers Associated with COCA2
To gain biological insights into the intriguing subtype COCA2, we first identified the most 
associated hallmark pathways by GSEA based on mRNA expression data (q < 0.1). Across 
the 33 cancer types, upregulated genes in COCA2 (relative to COCA1 and COCA3) showed 
consistently significant enrichment in the G2M checkpoint and DNA repair pathways; 
COCA2 correlated with other hallmark pathways but did so less consistently (Figure 6A). To 
confirm the preceding strong pathway associations, we further analyzed the pathway scores 
of the cell-cycle and DNA damage pathways derived from TCGA protein expression data for 
19 major cancer types with >100 samples (Akbani et al., 2014). COCA2 showed 
significantly higher cell-cycle and DNA damage response pathway scores in 12 and 9 cancer 
types, respectively (p < 0.05) (Figure 6B).
We next sought to identify somatic alternations that potentially drive the COCA2 subtypes. 
We first focused on significantly mutated genes (identified by MutSigCV) in each cancer 
type and assessed whether their mutation rates were different between the COCA2 samples 
and the remaining samples (Figure 6C). TP53 was differentially mutated in 13 cancer types 
(q < 0.1), including UCEC, LUAD, lower grade glioma (LGG), HNSC, COAD, and LIHC, 
in which significant survival patterns were observed (Figure 5F). Then we examined SCNA 
drivers by focusing on known oncogenes and tumor suppressors residing in amplification or 
deletion peaks (identified by GISTIC2) in each cancer type (Mermel et al., 2011; Zack et al., 
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2013). We found that COCA2 was associated with the amplifications of MYC and TERT 
and the deletions of PTEN and APC in multiple cancer types (q < 0.001) (Figure 6D). These 
potential SCNA drivers also showed consistent gene expression patterns across cancer types 
(Figure S7).
Low expression or mutated TP53 and MYC amplification are well-established drivers of 
cell-cycle and DNA damage repair response dysregulation (Campaner and Amati, 2012; 
Dang, 2012; Nakayama and Nakayama, 2006; Williams and Schumacher, 2016). Deletion or 
low expression of the tumor suppressor PTEN has been shown to drive cell-cycle 
progression, proliferation, and cell survival (Chalhoub and Baker, 2009; Minami et al., 2014; 
Ming and He, 2012). High expression of TERT, the catalytic subunit of telomerase, 
immortalizes cancer cells by promoting cell-cycle progression and increased survival. 
Furthermore, low expression of anaphase-promoting complex (APC) drives uncontrolled 
cell-cycle progression and proliferation. Therefore, we put forward a model in which 
mutated TP53 and amplified MYC are closely associated with primarily an upregulation of 
key ubiquitin-related enzymes, leading to an uncontrolled cell cycle, elevated DNA damage 
response, and ultimately poor survival for COCA2 patients (Figure 7). For the cell-cycle 
pathway, in addition to the upregulated core backbone components of SCF and the 
anaphase-promoting complex (APC/C), substrate recognition components such as CDH1, 
CDC20, and SKP2 showed upregulation, while FBXW7 and BTRC were downregulated. 
This result is consistent with the nature of the complexes’ substrates. For example, substrates 
of FBXW7 are oncoproteins, such as cyclin E, c-Myc, and Notch, while substrates of SKP2 
are tumor suppressors, such as p21, p27, and p57. For the DNA damage pathway, there was 
increased mRNA expression of RNF8, RNF168, RAD18, BRCA1, and UBE2N; the 
exception was HERC2. Increased DNA damage response intimately integrates with the 
dysregulation of cell-cycle progression and checkpoint control. This can potentially create a 
deleterious feedback loop, in which dysregulation of cell-cycle checkpoints, coupled with 
elevated DNA damage repair, leads to cells with unrepaired DNA damage entering 
replication, thereby amplifying the subsequent DNA damage response.
DISCUSSION
Using the latest TCGA multidimensional molecular profiling data, we performed 
comprehensive molecular characterization of the ubiquitin pathway of 1,024 genes across 
9,125 samples of 33 cancer types. There are three key findings in our study. First, we 
systematically cataloged driver candidates with significant mutation and SCNA patterns. 
Compared with top SCNA drivers, the profiles of mutation drivers are diverse across 
different cancer types. For example, BAP1 and VHL are frequently mutated in 
mesothelioma (MESO) and KIRC, respectively, whereas FBXW7 is enriched with hotspot 
mutations in UCEC and UCS but enriched with LoF mutations in ESCA, LUAD, LUSC, 
READ, SKCM, and STAD. These results suggest context-dependent oncogenic mechanisms 
of UBQ/DUB mutation drivers, which have been less appreciated in the field. Second, we 
show that compared to matched normal tissues, genes in the ubiquitin pathway tend to be 
overexpressed in a range of cancer types, and collectively, 71% of the upregulated genes are 
contributed by one of three mechanisms: somatic copy-number gain, reduced methylation-
mediated gene silencing, and reduced miRNA-mediated gene regulation in tumors. Finally, 
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the cross-platform integrative analysis reveals a group of patients that is consistently 
correlated with worse prognosis across nine cancer types. These tumor samples are 
associated with differential UBQ/DUB expression underlying the perturbation of many 
fundamental signaling pathways, notably cell-cycle progression and DNA damage repair, 
likely resulting from key molecular drivers such as TP53, MYC, TERT, PTEN, and APC. 
These striking and robust patterns highlight a unique value of the ubiquitin pathway in 
patient classification, conferring potential prognostic utility.
One major motivation for studying UBQs and DUBs is the potential to develop drugs that 
target the ubiquitin system (Salami and Crews, 2017). Thus far, the progress has been 
limited. This could be largely due to the lack of systemic characterization of significant 
driver mutations, SCNA patterns, and dysregulated expression profiles in the ubiquitin 
pathway across cancer types through an integrated genomic analysis that would provide 
clinically relevant drug candidates to the pharmaceutical industry. Another challenge is that 
unlike kinases, many components of the ubiquitin pathway lack a well-defined catalytic 
pocket, which makes them difficult to target by small molecules, although this obstacle 
might be overcome by the development of inhibitors that block specific protein-protein 
interaction. However, given its widespread impact, the potential for targeting some key 
components in the ubiquitin pathway for drug development through the controlled 
proteostasis mechanism is immense. Studies have provided a proof of principle that certain 
E3 ligases and DUBs are potential therapeutic targets that are amenable to inhibition by 
small molecules. For instance, MDM2 and SKP2, two oncogenic E3 ligases overexpressed 
in multiple cancer types, can be inhibited by Nutlins and Compound 25, respectively; these 
compounds have shown promising anti-tumor effects in xenograft tumor models (Chan et 
al., 2013; Vassilev et al., 2004). Moreover, the deubiquitinase USP7 has been shown to 
deubiquitinate several key cancer proteins, and P5091, a highly specific inhibitor of USP7, 
induced apoptosis in multiple myeloma cells (Chauhan et al., 2012). Our study suggests that 
targeting the ubiquitin pathway components involved in cell-cycle progression and DNA 
damage response pathways may offer promising opportunities for drug interventions, 
because these two pathways tightly correlate with the prognostically relevant tumor 
subtypes. In addition, mutually exclusive patterns between ubiquitin pathway genes and 
known actionable cancer genes suggest potential combination therapeutic strategies. This 
focused, systematic analysis of UBQ and DUB genes will lay a critical foundation for 
understanding the dysregulation of UBQ in cancer and provide unique insights into the 
development of related therapeutic approaches.
STAR★METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Deposited Data
TCGA somatic copy number 
alteration thresholded data
Genomic Data Commons https://gdc.cancer.gov/about-data/publications/pancanatlas
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REAGENT or RESOURCE SOURCE IDENTIFIER
TCGA somatic copy number 
segmentation data by 
Affymetrix SNP 6 array
Genomic Data Commons https://gdc.cancer.gov/about-data/publications/pancanatlas
TCGA somatic mutation data Genomic Data Commons https://gdc.cancer.gov/about-data/publications/pancanatlas
TCGA gene expression data Genomic Data Commons https://gdc.cancer.gov/about-data/publications/pancanatlas
TCGA reverse-phase protein 
array (RPPA) data
Genomic Data Commons https://gdc.cancer.gov/about-data/publications/pancanatlas.
TCGA DNA methylation 
data
Genomic Data Commons https://gdc.cancer.gov/about-data/publications/pancanatlas
TCGA miRNA-seq data Genomic Data Commons https://gdc.cancer.gov/about-data/publications/pancanatlas
TCGA patient clinic data Genomic Data Commons https://gdc.cancer.gov/about-data/publications/pancanatlas
Software and Algorithms
CoMEt (Leiserson et al., 2015) https://bioconductor.org/packages/release/bioc/html/coMET.html
MutSigCV (Lawrence et al., 2013) http://software.broadinstitute.org/cancer/software/genepattern/modules/docs/MutSigCV
GISTIC2.0 (Mermel et al., 2011) https://software.broadinstitute.org/software/cprg/?q=node/31
Gene Set Enrichment 
Analysis (GSEA)
(Mootha et al., 2003; 
Subramanian et al., 
2005)
http://software.broadinstitute.org/gsea/index.jsp
Cytoscape (Shannon et al., 2003) http://cytoscape.org
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to and will be fulfilled by the 
Lead Contact, Han Liang (hliang1@mdanderson.org).
METHOD DETAILS
Curation of UBQ and DUB gene sets—Given the diverse and integrative nature of the 
ubiquitin pathway, it was difficult to properly curate a definitive UBQ gene list. After an 
initial rigorous literature search, no established consensus was observed in the field beyond 
E1 and E2 enzymes, and the discovery of important E3 enzymes, adapters, and other E3-
associated genes was both escalating and in high debate. We therefore started our curation 
with a centralized, thorough database of UBQ and UBQ-associated genes, the Ubiquitin and 
Ubiquitin-like Conjugation Database (UUCD, http://uucd.biocuckoo.org/), which is 
continually updated and optimized as well as the most detailed and comprehensive available 
(Gao et al., 2013).
The UUCD database uses a multi-fold process to curate its UBQ genes relying on a 
combination of manual and computational methods. The first step in the process is a manual 
literature search using key words related to UBQ and UBQ-associated genes that can 
covalently recognize and modify other molecules, such as “ubiquitin,” “ubiquitination,” etc. 
This substantial, amassed list of genes was then distinguished into E1 gene (ThiF/MoeB), E2 
gene (UBC, UEV), and E3 gene categories based on the classification of their functional 
domains in the literature, thereby establishing a dual publication (PMID - Table S2) and 
UBQ domain correlation criterion for curation (Gao et al., 2013). Since a significant number 
of integral proteins participate in the function of E3 ligase complexes as adapters/receptors, 
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UUCD further categorized the E3-associated genes into two classifications based on domain 
sequence and associated function: E3 activity and E3 adaptor, where E3 activity refers to a 
functioning E3 enzyme in contrast to E3 adapters (E3-complex adaptor, substrate receptor, 
etc.) integrally participating in E3 enzymatic function (Gao et al., 2013). After properly 
categorizing the manually curated UBQ genes from the literature, UUCD applied a 
computational approach using UBQ protein sequences and hidden Markov models (HMM) 
to predict other possible UBQ enzymes and adapters yet to be discovered (HMM –Table S2). 
After aligning the protein sequences by MUSCLE, HMMER 3.0 was utilized to create 
hidden Markov model profiles of 1, 1, and 15 (http://uucd.biocuckoo.org/download/HMM) 
for E1, E2, and E3 UBQ genes, respectively. Moreover, these HMM models were further 
utilized along with hmmsearch to search all protein sequences to identify unknown UBQ 
genes and adapters, thus providing a much more expanded gene list of possible UBQ 
functionality (Eddy, 1998; Edgar, 2004; Gao et al., 2013). In this study, we chose to cast a 
wide net for potential E3 adapters/receptors in order for the most comprehensive analysis 
available.
Our final UBQ gene list was based on extracting the UBQ genes from the UUCD database 
(downloaded in March 2017) and then adding a filtering step to remove ubiquitin-like genes 
(enzymes and adapters) not directly associated with UBQ pathway function, such as 
sumoylation and ISGylation associated genes. As a result, our UBQ gene set included 929 
genes in total, including pre-established UUCD gene categories of E1 (8 genes, 1 predicted), 
E2 (39 genes, 2 predicted), and E3 (882 genes, 368 predicted). For E3 UBQ genes, they 
were further divided into E3 activity (387 genes, 78 predicted) and E3 adaptor (495 genes, 
290 predicted) (Figure S1A, Table S2).
In contrast to the complexity of the UBQ gene curation, DUB genes are far fewer in number 
and much easier to curate. A general consensus has been reached on their classification, thus 
a simple mining of the literature detailing an inventory of DUB genes leads to 
comprehensive gene coverage. In this study, we intersected 3 major DUB review articles and 
found a substantial overlap of DUB genes, where 80 of 91 total DUB genes were found in 
all 3 articles (Fraile et al., 2012; Komander et al., 2009; Nijman et al., 2005) (Figure S1B, 
Table S2). Notably, 4 genes from the MCPIP family, originally reported as DUB genes in 
Fraile et al., 2012, were later shown to exhibit no DUB activity and therefore filtered first 
before generating the final union of 91 DUB genes (Niu et al., 2013). In addition, we 
included four DUB genes recently discovered (Abdul Rehman et al., 2016). As a result, we 
created a final list of 95 DUB genes comprised of six major classes, including ubiquitin C-
terminal hydrolase (UCH), ubiquitin-specific protease (USP), Machado-Joseph domain 
(MJD), ovarian tumor (OTU), JAB1/MPN/Mov34 metalloprotease (JAMM), and motif 
interacting with Ub-containing DUB family (MINDY) (Table S2).
Somatic mutation analysis—We obtained TCGA pan-cancer somatic mutation data 
from Genomic Data Commons. Further filtering steps were used to eliminate artifacts and 
reduce false-positive calls. A) Only mutations with “PASS” in the “FILTER” column were 
retained for all cancer types except for ovarian serous cystadenocarcinoma (OV) and acute 
myeloid leukemia (LAML), for which we allowed “wga.” B) Hypermutated samples with > 
1,000 somatic mutations were removed, resulting in somatic mutation data for 8,811 
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samples for further analyses. Only non-silent somatic mutations were used to calculate 
mutation frequency. For each cancer type, MutSigCV (v1.4) was used to identify 
significantly mutated genes in each cancer cohort at a q value of 0.1. Across the pan-cancer 
cohort, hotspot mutations were defined as missense or in-frame mutations at the same 
protein amino acid in > 2 patient samples. The fraction of hotspot mutations per gene was 
calculated as the total number of hotspot mutations over the total number of non-silent 
mutations found in that gene. The fraction of LoF mutations (defined as Frame_Shift_Ins, 
Frame_Shift_Del, Nonsense_Mutation, Nonstop_Mutation, Splice_Site, and 
Tanslation_Start_Site) per gene was calculated as the total number of LoF mutations over 
the total number of non-silent mutations in that gene. Genes with > 30% hotspot mutations, 
< 20% LoF mutations, and ≥ 5 unique hotspot mutation positions were identified as enriched 
with hotspot mutations, while genes containing > 30% LoF mutations, < 30% hotspot 
mutations, and ≥ 10 LoF mutations were identified as enriched with LoF mutations. Mutual 
exclusivity for FBXW7 mutations and mutations in clinically actionable genes (annotated as 
in OncoKB, http://oncokb.org) was performed with the R package “cometExactTest.” To 
study the effects of FBXW7 mutations, PI3K pathway expression was calculated from 
protein levels of the PI3K/Akt pathway components as measured by RPPA with the 
following formula where E means expression:
EPI3K/Akt pathway = EAKTP473 + EAKTPT308 + EGSK3ALPHABETAPS21S9 + EGSK3PS9 + EP27PT157
+ EP27PT198 + EPRAS40PT246 + ETUBERINPT1462 − EINPP4B − EPTEN
Somatic copy-number alteration analysis—We obtained SCNA data of 9,125 patient 
samples from Genomic Data Commons and applied GISTIC2. For each cancer type, genes 
were considered to be amplified or deleted if they were located in the amplification peak or 
deletion peak at a q value of 0.25. The SCNA mutual exclusivity test was performed by 
employing the R package cometExactTest using the integer copy number data. Mutual 
exclusivity for MDM2 amplification and non-silent mutations in clinically actionable genes 
was carried out using the R package “cometExactTest.” For the pan-cancer SCNA clustering 
analysis, the integer copy numbers of UBQ and DUB genes were used with Ward’s method 
for consensus clustering.
RNA-seq analysis—We obtained normalized gene expression data from Genomic Data 
Commons. For the tumor-normal comparison, we performed a differential expression 
analysis between tumor and their matched normal samples for each of 16 cancer types using 
the Wilcoxon signed rank test and built the pre-ranked gene lists based on signed −log10 p 
values. For GSEA, the pre-ranked gene lists were then run against the UBQ, DUB and 
UBQ/DUB gene sets using GSEA Java GUI (version 2.3.3), respectively. For the pan-cancer 
expression-level clustering analysis, the normalized values from the root squared error 
method were log2-transformed and Z-normalized within each cancer type. Then, Pearson’s 
correlation and hierarchical average linkage clustering were applied to the top 800 most 
variable UBQ/DUB genes for consensus clustering.
MiRNA expression analysis—We obtained normalized miRNA expression data from 
Genomic Data Commons. To study the mechanisms underlying dysregulated UBQ/DUB 
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genes in cancer, based on the miRNA expression data of paired tumor–normal samples from 
562 patients, a paired t test was performed for each gene within each cancer type (5 cancer 
types with a sample size of > 20 pairs), where genes with significantly high or low 
expression in tumor samples were determined using a p-value cutoff of 0.05. We identified 
master miRNA regulators for UBQ and DUB genes based on two criteria. First, a miRNA 
has at least one seed region (2–8-mer) matched to the 3′UTR of any UBQ/DUB gene. 
Second, the Spearmen correlation of miRNA with the expression of the target gene was 
statistically significant (q < 10−5 and rho < −0.5). Cytoscape was used to visualize miRNA 
and the UBQ/DUB gene network.
DNA methylation analysis—We obtained DNA methylation 450K data from Genomic 
Data Commons. For each gene, one DNA methylation probe was selected based on the 
correlation with its mRNA expression level, and if multiple probes for a gene were available, 
the probe that had the most negative correlation value was selected. To study the 
mechanisms underlying dysregulated UBQ/DUB genes in cancer, based on the DNA 
methylation data of paired tumor–normal samples from 624 patients, a paired t test was 
performed for each gene within each cancer type (6 cancer types with a sample size of > 20 
pairs), where genes significantly hypermethylated or hypomethylated were determined using 
a p-value cutoff of 0.05. For the pan-cancer methylation-based clustering, consensus 
clustering was performed for the top 1,000 most variable probes for the UBQ/DUB genes, 
using the Euclidean distance and partitioning around medoids method.
Integrative clustering and patient survival analysis—We obtained TCGA patient 
clinical data from Genomic Data Commons. Clusters defined from individual platforms 
(SCNA, mRNA and DNA methylation) were coded into binary variables for each platform-
specific cluster. The matrix of 0 s and 1 s was then used as the input data matrix in the 
ConsensusClusterPlus R package to identify integrated relationships for the 9,125 patient 
samples. Pearson’s correlation and hierarchical clustering were used. Overall survival or 
disease-specific survival curves were compared using log-rank tests in the R package 
“survival.” To detect biological pathways associated with COCA clusters, for each cancer 
type, we performed a differential expression analysis between COCA2 and COCA1/COCA3 
samples using a t test and built the pre-ranked gene lists based on signed −log10 p values. 
For GSEA, the pre-ranked gene lists were then run against the seven cancer hallmark gene 
sets (MSigDB Collections: H) using GSEA Java GUI (version 2.3.3).
RPPA pathway score calculation—We obtained the normalized RPPA data from 
Genomic Data Commons and Z-normalized the data within each cancer type. Pathway 
scores for the cell cycle and DNA damage response pathways were calculated for each 
patient (total of 6,441 patients). To detect biological pathways associated with COCA 
clusters, RPPA pathway scores were used to test the pathway perturbations between COCA2 
and COCA1/COCA3 samples using a t test.
QUANTIFICATION AND STATISTICAL ANALYSES
Somatic mutation, SCNA, and RNA-seq analyses were based on 9,125 tumor samples; and 
miRNA expression, DNA methylation, and RPPA analyses were respectively based on 
Ge et al. Page 14
Cell Rep. Author manuscript; available in PMC 2018 April 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
7,939, 8,058, and 6,441 tumor samples due to limited data availability. Definitions of 
significance for various statistical tests are described and referenced in their respective 
sections in Methods.
DATA AND SOFTWARE AVAILABILITY
The raw data, processed data, and clinical data can be found at the legacy archive of the 
GDC (https://portal.gdc.cancer.gov/legacy-archive/search/f) and the PancanAtlas publication 
page (https://gdc.cancer.gov/about-data/publications/pancanatlas). The mutation data can be 
found here (https://gdc.cancer.gov/about-data/publications/mc3-2017). TCGA data can also 
be explored through the Broad Institute FireBrowse portal (http://gdac.broadinstitute.org) 
and the Memorial Sloan Kettering Cancer Center cBioPortal (http://www.cbioportal.org). 
Details for software availability are in the Key Resources Table.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Full molecular characterization of 1,024 ubiquitin pathway genes in 33 cancer 
types
• Systematically identify somatic driver candidates in the ubiquitin pathway
• Consistent prognostic patterns of tumor subtypes defined by ubiquitin 
pathway genes
• Propose a ubiquitin pathway mechanistic model underlying poor patient 
survival
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Figure 1. Frequently Mutated UBQ and DUB Genes as Potential Cancer Drivers
(A) UBQ and DUB genes are plotted as fractions of hotspot versus LoF mutations among all 
non-silent mutations across cancer types. Genes enriched with hotspot mutations are shown 
in red, genes enriched with LoF mutations are in blue, and FBXW7 is shown in orange, 
because it is enriched with both hotspot and LoF mutations. The circles represent UBQs, and 
the squares represent DUBs.
(B) Significantly mutated genes identified by MutSigCV in each cancer type are shown. The 
circles represent UBQs, and the squares represent DUBs; the circle or square size is 
proportional to the significance level. The fraction of patients harboring non-silent mutations 
in each gene is shown by color scale.
(C) UBQ and DUB genes enriched with hotspot and LoF mutations are mapped to different 
gene categories in the ubiquitin pathway. See also Figure S2.
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Figure 2. FBXW7 Is Enriched with Both Hotspot and Loss-of-Function Mutations
(A) Fractions of hotspot mutations versus LoF mutations among all non-silent mutations in 
FBXW7 are plotted for different cancer types. Cancer types enriched with hotspot mutations 
are shown in red, those enriched with LoF mutations are in blue, and those enriched with 
both hotspot and LoF mutations are in gray.
(B) WD40 domain structure of FBXW7 protein in which three arginines (R465, R479, and 
R505) are mutation hotspots and located at the substrate binding surface.
(C) Distributions of FBXW7 non-silent mutations in cancer types enriched with hotspot 
mutations (UCEC and UCS) and cancer types enriched with LoF mutations (ESCA, LUAD, 
LUSC, READ, SKCM, and STAD).
(D) FBXW7 mutations show mutually exclusive patterns with PIK3CA mutations in BLCA, 
CESC, and LUSC.
(E) Compared to tumors without mutations in FBXW7 or PI3K pathway genes, tumors with 
either FBXW7 or PI3K pathway mutations show elevated PI3K-Akt pathway activity, with 
*, p < 0.05.
The bottom and top of the box are the first and third quartiles, and the whiskers extend to 1.5 
IQR of the lower quartile and the upper quartile, respectively.
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Figure 3. Somatic Copy-Number Alterations of UBQ and DUB Genes
(A) Fractions of UBQ and DUB genes residing in the amplification or deletion peaks 
(identified by GISTIC2, q < 0.25) compared to non-UBQ/DUB genes in different cancer 
types. Significant deletion enrichments are detected with *p < 0.01.
(B) Most frequently amplified or deleted UBQ and DUB genes in multiple cancer types. The 
circle size is proportional to the significance level of GISTIC2 results.
(C) MDM2 amplification shows a mutually exclusive pattern with BRAF mutations in 
SKCM. TP53 mutations are shown for comparison. Each bar represents one patient; 
significance was assessed by Fisher’s exact test.
(D) TP53 protein and mRNA expression of tumor samples with MDM2 amplification versus 
those with BRAF mutations or wild-type (WT) samples, with *p < 0.05.
The bottom and top of the box are the first and third quartiles, and the whiskers extend to 1.5 
IQR of the lower quartile and the upper quartile, respectively.
(E) Graphical model showing the synergistic effect of MDM2 inhibitor and BRAF inhibitor.
See also Figure S3.
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Figure 4. Multiple Mechanisms Contribute to Upregulation of UBQ and DUB Genes in Cancer
(A) UBQ and DUB genes showed upregulation in tumor samples in seven cancer types 
(GSEA, q < 0.1).
(B) Proportions of upregulated, neutral, and downregulated UBQ/DUB genes in the seven 
cancer types (Wilcoxon signed rank test, q < 0.1).
(C) Top: proportions of copy-number amplification, neutral level, and deletions in 
upregulated and neutral UBQ/DUB gene groups in each cancer type. Middle: proportions of 
significantly decreased (paired t test, p < 0.05), decreased, and other expression of miRNA 
regulators in tumor samples relative to matched normal samples in upregulated and neutral 
UBQ/DUB gene groups. Bottom: proportions of significantly decreased (paired t test, p < 
0.05), decreased, and otherwise DNA methylation level in tumor samples relative to matched 
normal samples in upregulated and neutral UBQ/DUB gene groups. The asterisks indicate 
the significant proportion difference between the two groups (chi-square test, *q < 0.01). 
Right: Venn diagram showing the proportions of upregulated UBQ/DUB genes affected by 
different regulatory mechanisms.
See also Figures S4 and S5.
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Figure 5. Integrative Genomic Clustering and Patient Survival Analysis
(A–C) Heatmaps of consensus clustering for three platforms: RNA sequencing (RNA-seq)-
based mRNA expression (A), somatic copy-number alterations (B), and DNA methylation 
(C).
(D) Consensus matrix of integrative clustering showing three robust clusters (COCA1, 
COCA2, and COCA3).
(E) COCA clusters correlate with patient overall survival and disease-specific survival times 
in 10 and 9 cancer types, respectively.
(F) Kaplan-Meier plots of nine cancer types showing overall survival curves for three 
clusters of patients with log-rank p values.
See also Figure S6.
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Figure 6. Biological Pathways and Somatic Drivers Associated with the Poor Prognostic Tumor 
Subtypes (COCA2)
(A) Association of COCA2 with GSEA hallmark gene sets. Significant positive associations 
are shown in red, significant negative associations are shown in blue, and non-significant 
ones are shown in gray.
(B) Reverse-phase protein array (RPPA)-based pathway scores of cell-cycle and DNA repair 
between COCA2 samples (red box) and other samples (blue box).
The bottom and top of the box are the first and third quartiles, and the whiskers extend to 1.5 
IQR of the lower quartile and the upper quartile, respectively.
(C) Significantly mutated genes identified by MutSigCV, in which the mutations are 
significantly enriched (red) or depleted (blue) in COCA2 compared to COCA1 and COCA3 
in different cancer types (q < 0.1).
(D) SCNA drivers identified by GISTIC2, in which amplifications (for oncogenes) and 
deletions (for tumor suppressors) are significantly enriched in COCA2 compared to COCA1 
and COCA3 in different cancer types (q < 0.001).
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Figure 7. Mechanistic Model Describing the Biological Process Underlying COCA2 Subtypes
Somatic drivers identified for COCA2 subtypes (top) cause the expression-level changes of 
key UBQ and DUB genes in SCF complex, APC/C complex, and DNA damage response 
that underlie the aberrant activities of cell-cycle and DNA damage pathways (middle), 
thereby leading to poor patient survival of COCA2 subtypes (bottom). See also Figure S7.
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